1. Disease Information

1.1 What is the disease?

BEST1 bestrophinopathies are a group of autosomal dominant and autosomal recessive inherited retinal diseases (IRDs) caused by pathogenic variants in BEST1, most prominently manifesting as Best vitelliform macular dystrophy (BVMD; “Best disease”) and autosomal recessive bestrophinopathy (ARB), but also including ADVIRC, adult-onset vitelliform phenotypes, and BEST1‑associated retinitis pigmentosa. These conditions share a central theme of retinal pigment epithelium (RPE) dysfunction with characteristic subretinal material (vitelliform deposits and/or fluid) and frequent electro‑oculogram (EOG) abnormalities. (bianco2024multimodalimagingin pages 1-2, amato2023genetherapyin pages 2-3)

Concise overview (current understanding): BEST1 dysfunction perturbs RPE ion/fluid homeostasis and calcium‑regulated physiology; clinically this produces vitelliform lesions, subretinal/intraretinal fluid, abnormal EOG light rise, and progressive macular/retinal degeneration with variable severity and inheritance. (amato2023genetherapyin pages 1-2, khan2018normalelectrooculographyin pages 9-13)

1.2 Key identifiers (as available in evidence)

The retrieved evidence explicitly provides the following MIM/OMIM identifiers: - BVMD / Best disease: MIM #153700 (bianco2024multimodalimagingin pages 1-2) - BEST1 gene: MIM #607854 (bianco2024multimodalimagingin pages 1-2) - Autosomal recessive bestrophinopathy (ARB): OMIM 611809 (zhao2024clinicalandgenetic pages 1-2) - ADVIRC: MIM #193220 (bianco2024multimodalimagingin pages 1-2) - BEST1-associated retinitis pigmentosa: MIM #613194 (bianco2024multimodalimagingin pages 1-2) - Adult-onset vitelliform macular degeneration: OMIM 608161 (zhao2024clinicalandgenetic pages 1-2)

MONDO / Orphanet / ICD‑10/ICD‑11 / MeSH: Not available in the retrieved text evidence set; therefore, specific IDs cannot be asserted here without adding new database retrieval. (No relevant evidence found in provided corpus)

1.3 Synonyms and alternative names

• BVMD: “Best disease”, “Best vitelliform macular dystrophy” (beryozkin2024bestdiseaseglobal pages 1-2)
• AOFVD/AVMD: “adult‑onset foveomacular vitelliform dystrophy”, “adult vitelliform macular dystrophy/degeneration” (amato2023genetherapyin pages 2-3, zhao2024clinicalandgenetic pages 1-2)
• ARB: “autosomal recessive bestrophinopathy” (zhao2024clinicalandgenetic pages 1-2)
• BEST1 has historical alias VMD2 in some literature (khan2018normalelectrooculographyin pages 9-13)

1.4 Evidence source type

Information summarized here is derived from: - Aggregated disease-level resources in the form of cohort studies and reviews (e.g., imaging review, prevalence analysis) (bianco2024multimodalimagingin pages 1-2, beryozkin2024bestdiseaseglobal pages 1-2) - Primary human cohort/case series studies (e.g., ARB cohorts in China; BVMD/ARB clinical series) (zhao2024clinicalandgenetic pages 1-2, shi2023comprehensivegeneticanalysis pages 5-8) - Preclinical animal and in vitro models (canine models; iPSC‑RPE) (amato2023genetherapyin pages 6-7, khan2018normalelectrooculographyin pages 9-13)

2. Etiology

2.1 Disease causal factors

Primary cause: Germline pathogenic variants in BEST1. The BEST1 gene encodes bestrophin‑1, a homopentameric Ca2+-activated anion (chloride) channel expressed in RPE, and BEST1 pathogenic variants cause a phenotypic spectrum collectively termed “bestrophinopathies.” (amato2023genetherapyin pages 1-2, amato2023genetherapyin pages 2-3)

2.2 Risk factors

Genetic risk factors

• Causal variants: Numerous pathogenic variants across BEST1 (missense predominating overall; truncating variants enriched in ARB), including coding variants (e.g., p.Arg255Trp, p.Ala195Val) and noncoding deep intronic variants affecting splicing (e.g., c.867+97G>A). (shi2023comprehensivegeneticanalysis pages 1-2, zhao2024clinicalandgenetic pages 1-2)
• Founder effects: In a large Chinese ARB cohort, deep intronic variant c.867+97G>A was identified as a founder variant accounting for ~16% of alleles/heritability in that cohort. (shi2023comprehensivegeneticanalysis pages 2-2, shi2023comprehensivegeneticanalysis pages 5-8)

Environmental/lifestyle risk factors

The retrieved evidence does not provide robust epidemiologic environmental risk factors (e.g., smoking/diet/exposures). The conditions are primarily genetic with variable expressivity; modifiers are suspected but not quantified here. (khan2018normalelectrooculographyin pages 9-13)

2.3 Protective factors

No specific genetic or environmental protective factors were identified in the retrieved evidence corpus.

2.4 Gene–environment interactions

The retrieved evidence supports the concept that phenotype is variable and may involve modifiers, but does not provide a specific, validated gene–environment interaction. (khan2018normalelectrooculographyin pages 9-13)

3. Phenotypes

3.1 Major phenotype domains (with suggested HPO terms)

Below are common clinical phenotypes across the BEST1 spectrum. HPO term suggestions are provided as likely mappings.

1. Vitelliform subretinal lesions / deposits (fundus “egg‑yolk” lesion; multifocal yellow deposits)
2. Evidence: classic BVMD “egg‑yolk” lesion; ARB multifocal deposits throughout posterior pole/peripapillary region. (beryozkin2024bestdiseaseglobal pages 1-2, zhao2024clinicalandgenetic pages 1-2)

3. Suggested HPO: Vitelliform macular dystrophy (HP:0007757); Macular lesion (HP:0001103); Retinal flecks (HP:0001086)

4. Subretinal fluid and intraretinal cystic/schitic spaces (especially ARB)

5. Evidence: ARB OCT findings include subretinal fluid and intraretinal cystic/schitic spaces; changes may fluctuate longitudinally. (shakeel2024phenotypeandgenetic pages 2-3, cideciyan2023photoreceptorfunctionand pages 6-8)

6. Suggested HPO: Subretinal fluid (HP:0031889); Cystoid macular edema (HP:0000605); Retinoschisis (HP:0000579)

7. Abnormal electro‑oculogram (EOG) Arden ratio / reduced light peak

8. Evidence: EOG abnormality is a hallmark in BVMD/ARB; however normal EOG can occur in a minority (e.g., Arden ratio >1.65 in 8% in one large series). (amato2023genetherapyin pages 2-3)

9. Suggested HPO: Abnormal electrooculogram (HP:0025206) (term may vary by HPO release)

10. Visual acuity impairment / central vision loss

11. Evidence: BVMD can progress from normal fundus to lesion disruption and atrophy with visual decline; ARB can range broadly in acuity. (beryozkin2024bestdiseaseglobal pages 1-2, zhao2024clinicalandgenetic pages 1-2)

12. Suggested HPO: Reduced visual acuity (HP:0007663); Central scotoma (HP:0000603)

13. Macular neovascularization / choroidal neovascularization (CNV/CNVM)

14. Evidence: OCTA detects CNVs in many BVMD eyes; nonexudative CNVs are often reported. Real-world anti‑VEGF treatment for CNV is described in cohorts/case series. (amato2023genetherapyin pages 2-3, shakeel2024phenotypeandgenetic pages 2-3)

15. Suggested HPO: Choroidal neovascularization (HP:0007701)

16. Angle-closure glaucoma predisposition (especially ARB with short axial length/narrow angles)

17. Evidence: ARB cohort shows frequent shallow anterior chamber/narrow angles; misdiagnosis as angle-closure glaucoma common; preventive iridotomy and glaucoma surgeries used. (zhao2024clinicalandgenetic pages 1-2)
18. Suggested HPO: Angle-closure glaucoma (HP:0001132); Shallow anterior chamber (HP:0000594); Short axial length (HP:0000568)

3.2 Phenotype characteristics (age of onset, severity, progression)

• BVMD onset and course: median onset ~19 years (range 4–65), with slow progression and variable expressivity; imaging-based staging shows lesion composition evolves over time. (bianco2024multimodalimagingin pages 1-2, amato2023genetherapyin pages 2-3)
• Vision statistics in BVMD: one review reports ~75% of patients <40 years maintain ≥20/40 in at least one eye; ~75% of patients >30 years have ≤20/100 in at least one eye. (bianco2024multimodalimagingin pages 1-2)
• ARB onset and course: in a 2024 Chinese cohort (n=17), average onset 30.53 years (range 9–68) with acuity from light perception to 0.8; wide phenotypic variability and frequent anterior segment abnormalities. (zhao2024clinicalandgenetic pages 1-2)

3.3 Quality of life impact

The retrieved evidence does not provide formal QoL instrument results (e.g., EQ‑5D, VFQ‑25). However, progressive central vision loss and macular atrophy logically impair reading/driving and daily functioning; this should be confirmed with disease-specific QoL studies not present in the current corpus. (No direct QoL evidence in retrieved texts)

4. Genetic / Molecular Information

4.1 Causal gene

• Gene: BEST1 (bestrophin‑1) (amato2023genetherapyin pages 1-2)
• Protein: 585‑aa homopentameric Ca2+-activated anion channel, localized primarily to the RPE basolateral membrane (and also discussed in relation to ER localization). (amato2023genetherapyin pages 1-2, amato2023genetherapyin pages 7-8)

4.2 Pathogenic variant spectrum and classification

Variant types

• In a large Chinese ARB study, 54 distinct pathogenic variants included missense, nonsense, canonical splicing, frameshift, in-frame deletions, synonymous/regulatory changes, and deep intronic variants uncovered by WGS. (shi2023comprehensivegeneticanalysis pages 3-5, shi2023comprehensivegeneticanalysis pages 1-2)
• Deep intronic variants c.1101-491A>G and c.867+97G>A/T caused pseudoexon insertion or intron retention, generating premature termination codons consistent with transcript disruption (NMD) and loss-of-function. (shi2023comprehensivegeneticanalysis pages 1-2, shi2023comprehensivegeneticanalysis pages 2-3)

Mechanistic classes (current understanding)

BEST1 pathogenic variants are described in mechanistic categories: - Loss-of-function (LOF) - Dominant-negative (DN) (enabled by pentameric co-assembly, “poisoning” WT complexes) - Gain-of-function (GOF) (less common; may require silencing + augmentation) Gene therapy design implications follow from this classification. (amato2023genetherapyin pages 4-6, amato2023genetherapyin pages 1-2)

4.3 Allele frequency / founder variants (examples)

• Founder variant in Chinese ARB: c.867+97G>A (intron 7) accounted for 16% (20/125) of alleles in one Chinese cohort; haplotype analysis supported a founder effect. (shi2023comprehensivegeneticanalysis pages 5-8)
• Common coding alleles in that cohort included p.Arg255Trp (12.8%), p.Tyr44His (5.6%), and p.Ala195Val (5.6%). (shi2023comprehensivegeneticanalysis pages 5-8)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No validated modifier genes, epigenetic alterations, or chromosomal abnormalities were identified in the retrieved evidence set.

5. Environmental Information

No clear non-genetic causal environmental exposures were identified in the retrieved evidence. BEST1 bestrophinopathies are primarily genetic. (amato2023genetherapyin pages 2-3)

6. Mechanism / Pathophysiology

6.1 Molecular function and causal chain

Upstream trigger: pathogenic BEST1 variant → altered bestrophin‑1 channel quantity/function.

Core molecular role: bestrophin‑1 is a Ca2+-activated anion (Cl−) channel in RPE; its activity contributes to RPE electrophysiology and the EOG light rise. (amato2023genetherapyin pages 2-3, khan2018normalelectrooculographyin pages 9-13)

Proposed downstream steps (integrated from human and iPSC‑RPE evidence): 1. BEST1 dysfunction perturbs RPE chloride conductance and Ca2+-dependent physiology, including ER calcium handling/store-dependent signaling. (khan2018normalelectrooculographyin pages 9-13, amato2023genetherapyin pages 7-8) 2. Altered Ca2+ homeostasis affects multiple RPE processes (reported/implicated): photoreceptor outer segment (POS) phagocytosis, pigment granule migration, and membrane potential dynamics. (khan2018normalelectrooculographyin pages 9-13) 3. RPE support failure contributes to accumulation of subretinal material, fluid dysregulation (subretinal/intraretinal fluid), and progressive outer retinal disruption leading to photoreceptor dysfunction/degeneration and macular atrophy. (boon2009clinicalandmolecular pages 11-13, pfister2021phenotypicandgenetic pages 1-2)

6.2 Structural biology and pharmacologic modulation (2024 development)

Owji et al. (Nature Communications, Dec 2024) solved ligand-bound bestrophin structures and identified an extracellular positive allosteric site where PABA (4-aminobenzoic acid) binds (same site as GABA in Best2). PABA activates Best1 with EC50 ~192 nM and can rescue currents of multiple patient-derived dominant LOF Best1 mutants (A10T, R218H, L234P, A243T, Q293K, D302A) in co-expression experiments. This provides a mechanistically grounded small-molecule strategy complementary to gene therapy approaches. (owji2024neurotransmitterboundbestrophinchannel pages 5-6, owji2024neurotransmitterboundbestrophinchannel pages 1-2)

6.3 Suggested ontology terms

GO Biological Process (suggested): - Chloride transmembrane transport (GO:1902476) - Calcium ion homeostasis (GO:0055074) - Phagocytosis (GO:0006909) - Visual perception (GO:0007601)

GO Cellular Component (suggested): - Basolateral plasma membrane (GO:0016323) - Endoplasmic reticulum membrane (GO:0005789)

Cell types (CL terms, suggested): - Retinal pigment epithelial cell (CL:0002584) - Rod photoreceptor cell (CL:0000740) - Cone photoreceptor cell (CL:0000742)

7. Anatomical Structures Affected

7.1 Organ/system level

Primary system: Eye / visual system, with disease centered on: - Retina, especially macula (BVMD) and broader posterior pole involvement (ARB). (beryozkin2024bestdiseaseglobal pages 1-2, zhao2024clinicalandgenetic pages 1-2)

7.2 Tissue/cell level

• Retinal pigment epithelium (RPE) is the key primary affected tissue/cell type (BEST1 expression and electrophysiologic signature). (amato2023genetherapyin pages 1-2)

7.3 Subcellular localization

• Basolateral membrane of RPE; ER membrane localization also discussed (relevant to Ca2+ regulation). (amato2023genetherapyin pages 1-2, amato2023genetherapyin pages 7-8)

Suggested UBERON terms: - Retina (UBERON:0000966) - Macula lutea (UBERON:0001807) - Retinal pigment epithelium (UBERON:0001994) - Anterior chamber of eye (UBERON:0001769) (relevant to ARB angle closure predisposition)

8. Temporal Development

8.1 Onset

• BVMD: median ~19 years (range 4–65). (bianco2024multimodalimagingin pages 1-2)
• ARB: mean onset ~30.5 years (range 9–68) in one 2024 cohort; onset can also occur in childhood in other reports/series. (zhao2024clinicalandgenetic pages 1-2, pfister2021phenotypicandgenetic pages 2-3)

8.2 Progression

• Generally slowly progressive, with central photoreceptors often viable for decades, supporting a long interventional window. (amato2023genetherapyin pages 2-3)

9. Inheritance and Population

9.1 Inheritance patterns

• Autosomal dominant: typical for BVMD; also ADVIRC and other BEST1 phenotypes. (bianco2024multimodalimagingin pages 1-2, amato2023genetherapyin pages 2-3)
• Autosomal recessive: ARB (biallelic variants); recessive BVMD-like presentations exist. (zhao2024clinicalandgenetic pages 1-2, dhoble2024typicalbestvitelliform pages 7-11)

9.2 Epidemiology (statistics from recent sources)

• BVMD prevalence estimates vary: ~1/10,000 (USA), 2/10,000 (Sweden), 1/20,000 (Minnesota), 1.5/100,000 (Denmark). (bianco2024multimodalimagingin pages 1-2)
• Israel prevalence estimate for Best disease: 1 in 127,000, with differences by subgroup (1 in 76,000 Arab Muslims; 1 in 145,000 Jews). (beryozkin2024bestdiseaseglobal pages 1-2)

10. Diagnostics

10.1 Core clinical tests and typical findings

• Electro-oculogram (EOG): hallmark reduced light peak / reduced Arden ratio; however normal EOG can occur in a minority (e.g., 8% in one large series). (amato2023genetherapyin pages 2-3)
• Full-field ERG: typically normal or mildly reduced in BVMD; can be reduced in ARB. (bianco2024multimodalimagingin pages 1-2, pfister2021phenotypicandgenetic pages 1-2)
• OCT: essential for staging and quantifying subretinal material/fluid; shows characteristic vitelliform lesion morphology and outer retinal layer disruption. (amato2023genetherapyin pages 2-3, bianco2024multimodalimagingin pages 1-2)
• FAF / quantitative FAF: helps interpret lipofuscin-related signals and disease evolution; contributes to revised pathogenesis concepts (lipofuscin accumulation may be secondary). (bianco2024multimodalimagingin pages 1-2)
• OCT-A: detects macular neovascularization and nonexudative CNV. (amato2023genetherapyin pages 2-3, bianco2024multimodalimagingin pages 1-2)
• Genetic testing: emphasized as “gold standard” due to variable clinical presentation. (beryozkin2024bestdiseaseglobal pages 1-2)

10.2 Differential diagnosis and diagnostic pitfalls

• BVMD vs AOFVD/pattern dystrophy: similar vitelliform lesions; age of onset and EOG/angiographic features can help, and genetics clarifies. (makati2014electrooculographyandoptical pages 3-4, zhao2024clinicalandgenetic pages 1-2)
• ARB may be misdiagnosed as angle-closure glaucoma, Best disease, or central serous chorioretinopathy with CNV. (zhao2024clinicalandgenetic pages 1-2, zhao2024clinicalandgenetic pages 2-4)

11. Outcome / Prognosis

11.1 Vision outcomes

• BVMD prognosis is variable; many younger patients retain good acuity, but later stages with atrophy/fibrosis reduce acuity. Quantitative visual outcomes in one review: 75% <40 years retain ≥20/40 (≥1 eye) while 75% >30 years have ≤20/100 (≥1 eye). (bianco2024multimodalimagingin pages 1-2)

11.2 Prognostic factors

Specific prognostic biomarkers are not established in the retrieved evidence; however, multimodal imaging (OCT staging, ellipsoid zone integrity, neovascularization status) is emphasized for monitoring and prognostication. (bianco2024multimodalimagingin pages 1-2)

12. Treatment

12.1 Current real-world management

No approved disease-modifying pharmacotherapy is established in the retrieved evidence; management focuses on monitoring and treating complications.

Complication-directed care: - Anti-VEGF therapy for CNV/CNVM (e.g., bevacizumab, conbercept) is used when neovascular complications occur. (shakeel2024phenotypeandgenetic pages 2-3, zhao2024clinicalandgenetic pages 2-4) - Angle-closure risk management in ARB: preventive laser peripheral iridotomy and glaucoma surgery (trabeculectomy + iridotomy) were used in a 2024 cohort. (zhao2024clinicalandgenetic pages 1-2, zhao2024clinicalandgenetic pages 2-4)

Suggested MAXO terms (examples): - Anti-VEGF therapy (MAXO:0001298) (term label may vary) - Laser peripheral iridotomy (MAXO term not confirmed in evidence) - Trabeculectomy (MAXO term not confirmed in evidence) - Genetic counseling (MAXO:0000079) (term label may vary)

12.2 Advanced therapeutics and latest research (2023–2024 prioritized)

Gene therapy / gene augmentation (preclinical → clinical)

Preclinical gene augmentation in canine models shows lesion reversal after subretinal AAV delivery with sustained effects up to 245 weeks and no inflammatory response in reported experiments, supporting a translational basis for human trials. (amato2023genetherapyin pages 6-7)

Small-molecule channel activation (Dec 2024)

PABA and related small molecules activate Best1 and can rescue currents for multiple dominant LOF mutants in vitro, suggesting a potential pharmacologic approach for dominant LOF bestrophinopathies. (owji2024neurotransmitterboundbestrophinchannel pages 5-6)

12.3 Clinical trials and real-world implementations

• NCT05809635 (started 2021-03-30; recruiting): Prospective natural history study for BEST1 vitelliform macular dystrophy; endpoints include OCT, FAF, NIR-AF, qAF, EOG, ERG, perimetry, etc., to define sensitive outcome measures for future clinical trials. (NCT05809635 chunk 1)
• NCT07185256 (Opus Genetics; 2025; recruiting): Interventional study of subretinal OPGx-BEST1 in BVMD or ARB; includes patient-reported outcomes and genetic eligibility criteria. (NCT07185256 chunk 2)
• NCT02162953 (Mayo Clinic; completed 2022-12-31): Observational study collecting samples to generate iPSC models of Best disease and other BEST1-related diseases (disease modeling resource). (NCT02162953 chunk 1)

13. Prevention

Primary prevention is not generally possible for monogenic inherited retinal diseases, but genetic counseling, cascade testing, and reproductive options are key.

• Secondary prevention: early detection through family screening and genetics to enable monitoring for CNV and angle-closure risk (especially in ARB). (beryozkin2024bestdiseaseglobal pages 1-2, zhao2024clinicalandgenetic pages 1-2)

14. Other Species / Natural Disease

• Naturally occurring disease models are described in dogs (canine multifocal retinopathy due to biallelic cBEST1 mutations), which recapitulate many human features and have been used for preclinical AAV gene augmentation studies. (amato2023genetherapyin pages 6-7)

15. Model Organisms

15.1 Canine model

Canine multifocal retinopathy (cmr) caused by biallelic BEST1 mutations reproduces clinical/molecular/histologic features and has enabled long-term AAV augmentation studies. (amato2023genetherapyin pages 6-7)

15.2 Mouse models

BEST1 knockout mice reportedly show no retinal phenotype, whereas a knock-in model with W93C recapitulates BVMD-like features with dominant inheritance/incomplete penetrance and reduced EOG light peak. (amato2023genetherapyin pages 6-7)

15.3 iPSC-RPE models (human)

Patient-derived iPSC‑RPE models demonstrate reduced phagocytosis and stress-dependent autofluorescent material accumulation, plus altered ER-dependent Ca2+ currents; these systems have been used to test rescue strategies including augmentation and silencing+augmentation for GOF/DN contexts. (khan2018normalelectrooculographyin pages 9-13, amato2023genetherapyin pages 7-8)

Expert opinions and analysis (from authoritative sources)

• Reviews emphasize that bestrophinopathies are slowly progressive with a wide therapeutic window, and that the presence of quantifiable subretinal material makes them attractive for clinical-trial endpoints. (amato2023genetherapyin pages 1-2)
• Genetic testing is emphasized as essential/gold standard because phenotypes are variable and can overlap with other maculopathies. (beryozkin2024bestdiseaseglobal pages 1-2)

Direct abstract quotes (where available in retrieved evidence)

• Gene therapy review: bestrophinopathies are collectively named and BEST1 encodes a channel localized to RPE basolateral membrane (from abstract). (amato2023genetherapyin pages 1-2)
• Imaging review abstract: “Quantitative fundus autofluorescence studies informed us that lipofuscin accumulation… is unlikely to be a primary effect of the genetic defect.” (bianco2024multimodalimagingin pages 1-2)
• Owji et al. abstract: “PABA treatment rescues the functional deficiency of patient-derived Best1 mutations.” (owji2024neurotransmitterboundbestrophinchannel pages 1-2)

Gaps / not available in current evidence set

• MONDO, Orphanet, ICD‑10/11, MeSH identifiers were not present in retrieved texts.
• Formal QoL metrics and systematic environmental risk/protective factors were not present.
• Modifier genes and epigenetic signatures were not established in the retrieved evidence corpus.

Key references (URLs and publication dates)

• Bianco et al. European Journal of Ophthalmology (Mar 2024): https://doi.org/10.1177/11206721231166434 (bianco2024multimodalimagingin pages 1-2)
• Beryozkin et al. IOVS (Feb 2024): https://doi.org/10.1167/iovs.65.2.39 (beryozkin2024bestdiseaseglobal pages 1-2)
• Zhao et al. BMC Ophthalmology (Jul 2024): https://doi.org/10.1186/s12886-024-03574-8 (zhao2024clinicalandgenetic pages 1-2)
• Shi et al. IOVS (Sep 2023): https://doi.org/10.1167/iovs.64.12.37 (shi2023comprehensivegeneticanalysis pages 1-2)
• Amato et al. Saudi Journal of Ophthalmology (Oct 2023): https://doi.org/10.4103/sjopt.sjopt_175_23 (amato2023genetherapyin pages 1-2)
• Owji et al. Nature Communications (Dec 2024): https://doi.org/10.1038/s41467-024-54938-z (owji2024neurotransmitterboundbestrophinchannel pages 1-2)
• ClinicalTrials.gov NCT05809635: https://clinicaltrials.gov/study/NCT05809635 (NCT05809635 chunk 1)
• ClinicalTrials.gov NCT07185256: https://clinicaltrials.gov/study/NCT07185256 (NCT07185256 chunk 2)
• ClinicalTrials.gov NCT02162953: https://clinicaltrials.gov/study/NCT02162953 (NCT02162953 chunk 1)

References

1. (bianco2024multimodalimagingin pages 1-2): Lorenzo Bianco, Alessandro Arrigo, Alessio Antropoli, Alessandro Berni, Andrea Saladino, Manuel AP Vilela, Ahmad M Mansour, Francesco Bandello, and Maurizio Battaglia Parodi. Multimodal imaging in best vitelliform macular dystrophy: literature review and novel insights. European Journal of Ophthalmology, 34:39-51, Mar 2024. URL: https://doi.org/10.1177/11206721231166434, doi:10.1177/11206721231166434. This article has 23 citations and is from a peer-reviewed journal.

2. (beryozkin2024bestdiseaseglobal pages 1-2): Avigail Beryozkin, Ifat Sher, Miriam Ehrenberg, Dinah Zur, Hadas Newman, Libe Gradstein, Francis Simaan, Ygal Rotenstreich, Nitza Goldenberg-Cohen, Irit Bahar, Anat Blumenfeld, Antonio Rivera, Boris Rosin, Iris Deitch-Harel, Ido Perlman, Hadas Mechoulam, Itay Chowers, Rina Leibu, Tamar Ben-Yosef, Eran Pras, Eyal Banin, Dror Sharon, and Samer Khateb. Best disease: global mutations review, genotype–phenotype correlation, and prevalence analysis in the israeli population. Investigative Opthalmology & Visual Science, 65:39, Feb 2024. URL: https://doi.org/10.1167/iovs.65.2.39, doi:10.1167/iovs.65.2.39. This article has 6 citations.

3. (amato2023genetherapyin pages 2-3): Alessia Amato, Nida Wongchaisuwat, Andrew Lamborn, Ryan Schmidt, Lesley Everett, Paul Yang, and Mark E. Pennesi. Gene therapy in bestrophinopathies: insights from preclinical studies in preparation for clinical trials. Saudi Journal of Ophthalmology, 37:287-295, Oct 2023. URL: https://doi.org/10.4103/sjopt.sjopt_175_23, doi:10.4103/sjopt.sjopt_175_23. This article has 8 citations.

4. (owji2024neurotransmitterboundbestrophinchannel pages 5-6): Aaron P. Owji, Jingyun Dong, Alec Kittredge, Jiali Wang, Yu Zhang, and Tingting Yang. Neurotransmitter-bound bestrophin channel structures reveal small molecule drug targeting sites for disease treatment. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-54938-z, doi:10.1038/s41467-024-54938-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

5. (zhao2024clinicalandgenetic pages 1-2): Dongsheng Zhao, Victoria Y. Gu, Yafu Wang, Jie Peng, Jiao Lyu, Ping Fei, Yu Xu, Xiang Zhang, and Peiquan Zhao. Clinical and genetic features in autosomal recessive bestrophinopathy in chinese cohort. BMC Ophthalmology, Jul 2024. URL: https://doi.org/10.1186/s12886-024-03574-8, doi:10.1186/s12886-024-03574-8. This article has 4 citations and is from a peer-reviewed journal.

6. (shi2023comprehensivegeneticanalysis pages 5-8): Jie-Feng Shi, Lu Tian, Tengyang Sun, Xiao Zhang, K. Xu, Yue Xie, Xiaoyan Peng, Xin Tang, Zidan Jin, and Yang Li. Comprehensive genetic analysis unraveled the missing heritability and a founder variant of best1 in a chinese cohort with autosomal recessive bestrophinopathy. Investigative Opthalmology & Visual Science, 64:37, Sep 2023. URL: https://doi.org/10.1167/iovs.64.12.37, doi:10.1167/iovs.64.12.37. This article has 8 citations.

7. (shi2023comprehensivegeneticanalysis pages 1-2): Jie-Feng Shi, Lu Tian, Tengyang Sun, Xiao Zhang, K. Xu, Yue Xie, Xiaoyan Peng, Xin Tang, Zidan Jin, and Yang Li. Comprehensive genetic analysis unraveled the missing heritability and a founder variant of best1 in a chinese cohort with autosomal recessive bestrophinopathy. Investigative Opthalmology & Visual Science, 64:37, Sep 2023. URL: https://doi.org/10.1167/iovs.64.12.37, doi:10.1167/iovs.64.12.37. This article has 8 citations.

8. (dhoble2024typicalbestvitelliform pages 1-7): Pankaja Dhoble, Anthony G. Robson, Andrew R. Webster, and Michel Michaelides. Typical best vitelliform dystrophy secondary to biallelic variants in best1. Ophthalmic Genetics, 45:38-43, Mar 2024. URL: https://doi.org/10.1080/13816810.2023.2188227, doi:10.1080/13816810.2023.2188227. This article has 2 citations and is from a peer-reviewed journal.

9. (dhoble2024typicalbestvitelliform pages 7-11): Pankaja Dhoble, Anthony G. Robson, Andrew R. Webster, and Michel Michaelides. Typical best vitelliform dystrophy secondary to biallelic variants in best1. Ophthalmic Genetics, 45:38-43, Mar 2024. URL: https://doi.org/10.1080/13816810.2023.2188227, doi:10.1080/13816810.2023.2188227. This article has 2 citations and is from a peer-reviewed journal.

10. (makati2014electrooculographyandoptical pages 3-4): Ravie Makati, Diana Shechtman, Eulogio Besada, and Joseph J. Pizzimenti. Electrooculography and optical coherence tomography reveal late-onset best disease. Optometry and Vision Science, 91:e274–e277, Nov 2014. URL: https://doi.org/10.1097/opx.0000000000000403, doi:10.1097/opx.0000000000000403. This article has 4 citations and is from a peer-reviewed journal.

11. (amato2023genetherapyin pages 1-2): Alessia Amato, Nida Wongchaisuwat, Andrew Lamborn, Ryan Schmidt, Lesley Everett, Paul Yang, and Mark E. Pennesi. Gene therapy in bestrophinopathies: insights from preclinical studies in preparation for clinical trials. Saudi Journal of Ophthalmology, 37:287-295, Oct 2023. URL: https://doi.org/10.4103/sjopt.sjopt_175_23, doi:10.4103/sjopt.sjopt_175_23. This article has 8 citations.

12. (khan2018normalelectrooculographyin pages 9-13): Kamron N. Khan, Farrah Islam, Graham E. Holder, Anthony Robson, Andrew R. Webster, Anthony T. Moore, and Michel Michaelides. Normal electrooculography in best disease and autosomal recessive bestrophinopathy. Retina, 38:379–386, Feb 2018. URL: https://doi.org/10.1097/iae.0000000000001523, doi:10.1097/iae.0000000000001523. This article has 23 citations.

13. (amato2023genetherapyin pages 6-7): Alessia Amato, Nida Wongchaisuwat, Andrew Lamborn, Ryan Schmidt, Lesley Everett, Paul Yang, and Mark E. Pennesi. Gene therapy in bestrophinopathies: insights from preclinical studies in preparation for clinical trials. Saudi Journal of Ophthalmology, 37:287-295, Oct 2023. URL: https://doi.org/10.4103/sjopt.sjopt_175_23, doi:10.4103/sjopt.sjopt_175_23. This article has 8 citations.

14. (shi2023comprehensivegeneticanalysis pages 2-2): Jie-Feng Shi, Lu Tian, Tengyang Sun, Xiao Zhang, K. Xu, Yue Xie, Xiaoyan Peng, Xin Tang, Zidan Jin, and Yang Li. Comprehensive genetic analysis unraveled the missing heritability and a founder variant of best1 in a chinese cohort with autosomal recessive bestrophinopathy. Investigative Opthalmology & Visual Science, 64:37, Sep 2023. URL: https://doi.org/10.1167/iovs.64.12.37, doi:10.1167/iovs.64.12.37. This article has 8 citations.

15. (shakeel2024phenotypeandgenetic pages 2-3): Areeba Shakeel, Darshan M Bhatt, Lingam Gopal, Rajiv Raman, Chetan Rao, S. Sripriya, and Muna Bhende. Phenotype and genetic spectrum of six indian patients with bestrophinopathy. Taiwan Journal of Ophthalmology, 14:602-608, Oct 2024. URL: https://doi.org/10.4103/tjo.tjo-d-24-00080, doi:10.4103/tjo.tjo-d-24-00080. This article has 2 citations.

16. (cideciyan2023photoreceptorfunctionand pages 6-8): Artur V. Cideciyan, Samuel G. Jacobson, Alexander Sumaroka, Malgorzata Swider, Arun K. Krishnan, Rebecca Sheplock, Alexandra V. Garafalo, Karina E. Guziewicz, Gustavo D. Aguirre, William A. Beltran, Yoshitsugu Matsui, Mineo Kondo, and Elise Heon. Photoreceptor function and structure in retinal degenerations caused by biallelic best1 mutations. Vision Research, 203:108157, Feb 2023. URL: https://doi.org/10.1016/j.visres.2022.108157, doi:10.1016/j.visres.2022.108157. This article has 5 citations and is from a peer-reviewed journal.

17. (amato2023genetherapyin pages 7-8): Alessia Amato, Nida Wongchaisuwat, Andrew Lamborn, Ryan Schmidt, Lesley Everett, Paul Yang, and Mark E. Pennesi. Gene therapy in bestrophinopathies: insights from preclinical studies in preparation for clinical trials. Saudi Journal of Ophthalmology, 37:287-295, Oct 2023. URL: https://doi.org/10.4103/sjopt.sjopt_175_23, doi:10.4103/sjopt.sjopt_175_23. This article has 8 citations.

18. (shi2023comprehensivegeneticanalysis pages 3-5): Jie-Feng Shi, Lu Tian, Tengyang Sun, Xiao Zhang, K. Xu, Yue Xie, Xiaoyan Peng, Xin Tang, Zidan Jin, and Yang Li. Comprehensive genetic analysis unraveled the missing heritability and a founder variant of best1 in a chinese cohort with autosomal recessive bestrophinopathy. Investigative Opthalmology & Visual Science, 64:37, Sep 2023. URL: https://doi.org/10.1167/iovs.64.12.37, doi:10.1167/iovs.64.12.37. This article has 8 citations.

19. (shi2023comprehensivegeneticanalysis pages 2-3): Jie-Feng Shi, Lu Tian, Tengyang Sun, Xiao Zhang, K. Xu, Yue Xie, Xiaoyan Peng, Xin Tang, Zidan Jin, and Yang Li. Comprehensive genetic analysis unraveled the missing heritability and a founder variant of best1 in a chinese cohort with autosomal recessive bestrophinopathy. Investigative Opthalmology & Visual Science, 64:37, Sep 2023. URL: https://doi.org/10.1167/iovs.64.12.37, doi:10.1167/iovs.64.12.37. This article has 8 citations.

20. (amato2023genetherapyin pages 4-6): Alessia Amato, Nida Wongchaisuwat, Andrew Lamborn, Ryan Schmidt, Lesley Everett, Paul Yang, and Mark E. Pennesi. Gene therapy in bestrophinopathies: insights from preclinical studies in preparation for clinical trials. Saudi Journal of Ophthalmology, 37:287-295, Oct 2023. URL: https://doi.org/10.4103/sjopt.sjopt_175_23, doi:10.4103/sjopt.sjopt_175_23. This article has 8 citations.

21. (boon2009clinicalandmolecular pages 11-13): CAMIEL J. F. BOON, THOMAS THEELEN, ELISABETH H. HOEFSLOOT, MARY J. VAN SCHOONEVELD, JAN E. E. KEUNEN, FRANS P. M. CREMERS, B JEROEN KLEVERING, and CAREL B. HOYNG. Clinical and molecular genetic analysis of best vitelliform macular dystrophy. Retina, 29:835-847, Jun 2009. URL: https://doi.org/10.1097/iae.0b013e31819d4fda, doi:10.1097/iae.0b013e31819d4fda. This article has 88 citations.

22. (pfister2021phenotypicandgenetic pages 1-2): Tyler A. Pfister, Wadih M. Zein, Catherine A. Cukras, Hatice N. Sen, Ramiro S. Maldonado, Laryssa A. Huryn, and Robert B. Hufnagel. Phenotypic and genetic spectrum of autosomal recessive bestrophinopathy and best vitelliform macular dystrophy. Investigative Opthalmology & Visual Science, 62:22, May 2021. URL: https://doi.org/10.1167/iovs.62.6.22, doi:10.1167/iovs.62.6.22. This article has 22 citations.

23. (owji2024neurotransmitterboundbestrophinchannel pages 1-2): Aaron P. Owji, Jingyun Dong, Alec Kittredge, Jiali Wang, Yu Zhang, and Tingting Yang. Neurotransmitter-bound bestrophin channel structures reveal small molecule drug targeting sites for disease treatment. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-54938-z, doi:10.1038/s41467-024-54938-z. This article has 6 citations and is from a highest quality peer-reviewed journal.

24. (pfister2021phenotypicandgenetic pages 2-3): Tyler A. Pfister, Wadih M. Zein, Catherine A. Cukras, Hatice N. Sen, Ramiro S. Maldonado, Laryssa A. Huryn, and Robert B. Hufnagel. Phenotypic and genetic spectrum of autosomal recessive bestrophinopathy and best vitelliform macular dystrophy. Investigative Opthalmology & Visual Science, 62:22, May 2021. URL: https://doi.org/10.1167/iovs.62.6.22, doi:10.1167/iovs.62.6.22. This article has 22 citations.

25. (zhao2024clinicalandgenetic pages 2-4): Dongsheng Zhao, Victoria Y. Gu, Yafu Wang, Jie Peng, Jiao Lyu, Ping Fei, Yu Xu, Xiang Zhang, and Peiquan Zhao. Clinical and genetic features in autosomal recessive bestrophinopathy in chinese cohort. BMC Ophthalmology, Jul 2024. URL: https://doi.org/10.1186/s12886-024-03574-8, doi:10.1186/s12886-024-03574-8. This article has 4 citations and is from a peer-reviewed journal.

26. (NCT05809635 chunk 1): Stephen H. Tsang. Study of BEST1 Vitelliform Macular Dystrophy. Columbia University. 2021. ClinicalTrials.gov Identifier: NCT05809635

27. (NCT07185256 chunk 2): Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Opus Genetics, Inc. 2025. ClinicalTrials.gov Identifier: NCT07185256

28. (NCT02162953 chunk 1): Alan D. Marmorstein, Ph.D.. Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.. Mayo Clinic. 2014. ClinicalTrials.gov Identifier: NCT02162953

BEST1 Bestrophinopathies: Comprehensive Disease Characteristics Report

Summary

BEST1 bestrophinopathies are a clinically heterogeneous group of inherited retinal dystrophies caused by mutations in the BEST1 gene (chromosome 11q12.3), which encodes bestrophin-1, a pentameric calcium-activated chloride channel (CaCC) predominantly expressed on the basolateral membrane of the retinal pigment epithelium (RPE). Over 250 pathogenic missense mutations and additional frameshift, nonsense, splice-site, and deep intronic variants have been identified, giving rise to five clinically distinct phenotypes: Best Vitelliform Macular Dystrophy (BVMD; OMIM #153700), Autosomal Recessive Bestrophinopathy (ARB; OMIM #611809), Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC; OMIM #193220), Retinitis Pigmentosa type 50 (RP50; OMIM #613194), and Adult-Onset Vitelliform Macular Dystrophy (AVMD). The ClinVar database now contains 1,047 BEST1 variant entries, of which 693 are classified as pathogenic or likely pathogenic.

The core pathophysiology involves disruption of RPE chloride conductance and calcium homeostasis through the BEST1-CaV1.3 L-type calcium channel axis, leading to impaired transepithelial fluid transport, defective phagocytosis of photoreceptor outer segments, accelerated lipofuscin accumulation, and progressive vitelliform material deposition at the macula. In dominant forms, mutant bestrophin-1 exerts dominant-negative effects on pentameric channel assembly, while certain mutations (e.g., p.P233L, p.P346H) undergo Hsp70/CHIP E3 ligase-mediated ubiquitination at Lys149, triggering protein degradation and membrane mislocalization. In recessive forms, biallelic loss-of-function mutations cause more severe and widespread retinal dysfunction, including anterior segment anomalies such as shallow anterior chambers and angle-closure glaucoma.

Therapeutically, there is no approved treatment for bestrophinopathies. However, the first human gene therapy trial (NCT07185256, OPGx-BEST1, Phase 1b/2a) began recruiting in September 2025, and preclinical studies have demonstrated that AAV-mediated BEST1 gene augmentation and CRISPR-Cas9 gene editing can restore chloride channel activity in iPSC-RPE disease models. The largest natural history study of BVMD (n=222 patients) confirms slow visual acuity decline (~0.013 logMAR/year), establishing key endpoints for future clinical trials. Deep intronic variants identified by whole-genome sequencing have resolved the missing heritability problem in Chinese ARB cohorts, underscoring the need for comprehensive genetic testing beyond standard exome approaches.

1. Disease Information

Overview

BEST1 bestrophinopathies are a group of clinically distinct inherited retinal dystrophies caused by mutations in the BEST1 gene (formerly VMD2), which encodes Bestrophin-1, a calcium-activated chloride channel (CaCC) predominantly expressed in the retinal pigment epithelium (RPE). These disorders primarily affect the macula and surrounding retinal regions, leading to progressive central vision loss. The spectrum encompasses at least five clinically recognized phenotypes ranging from juvenile-onset macular dystrophy to retinitis pigmentosa (PMID: 31884648, PMID: 33738427).

"Bestrophinopathies are a group of clinically distinct inherited retinal dystrophies that lead to the gradual loss of vision in and around the macular area. There are no treatments for patients suffering from bestrophinopathies, and no measures can be taken to prevent visual deterioration in those who have inherited disease-causing mutations." (PMID: 31884648)

Key Identifiers

Common Synonyms and Alternative Names

• Best vitelliform macular dystrophy (BVMD)
• Best disease / Best macular dystrophy (BMD)
• Vitelliform macular dystrophy type 2 (VMD2)
• Autosomal recessive bestrophinopathy (ARB)
• Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
• Retinitis pigmentosa 50 (RP50)
• Adult-onset vitelliform macular dystrophy (AVMD) (when BEST1-related)

Information Source

This report is derived from aggregated disease-level resources including primary literature (108 PubMed-indexed publications), OMIM, Orphanet, ClinVar, GeneReviews, and published clinical cohort studies. The largest patient-level datasets include the BVMD natural history study (n=222; PMID: 38278445) and ARB cohort studies (PMID: 41421761; PMID: 33039401).

2. Etiology

Disease Causal Factors

BEST1 bestrophinopathies are purely genetic disorders caused by mutations in the BEST1 gene located at chromosome 11q12.3. No environmental or infectious causes are known.

Risk Factors

Genetic Risk Factors

• Causal variants: Over 250 distinct pathogenic mutations identified in BEST1, predominantly missense variants (PMID: 31570112, PMID: 36378562).
• Mutation hotspots: Variants cluster in functionally critical regions including the transmembrane domains (TM2-TM4), calcium-binding regions, and the cytoplasmic domain (exons 2-8). Variant c.898G>A was identified as a hotspot in the Chinese population (PMID: 32278767).
• Deep intronic variants (DIVs): c.1101-491A>G (pseudoexon insertion), c.867+97G>A (intron retention, Chinese founder), c.867+97G>T resolved missing heritability in 20/63 Chinese ARB families (PMID: 37747403).
• Founder variants: Egyptian founder variant c.365G>C (p.Arg122Pro) in 12 patients from 9 unrelated consanguineous families (PMID: 40414863).

"A total of 9 variants on the BEST1 gene were identified, containing 7 missense variants, 1 nonsense variant, and 1 frameshift variant" (PMID: 36378562)

Environmental Risk Factors

No environmental risk factors are established for bestrophinopathies. The disease is entirely genetically determined. Age is the primary non-genetic factor affecting disease progression and visual acuity outcomes.

Protective Factors

• Genetic: Variable penetrance in some families suggests modifier genes, though none identified. In the Slovenian cohort, mutation p.Arg105Gly showed incomplete clinical penetrance (PMID: 27775230).
• Environmental: No established environmental protective factors.

Gene-Environment Interactions

No gene-environment interactions have been documented. Variable expressivity and penetrance are thought to reflect genetic background differences rather than environmental influences.

3. Phenotypes

Best Vitelliform Macular Dystrophy (BVMD) - The Classic Phenotype

BVMD progresses through recognized clinical stages:

Phenotype Characteristics

• Age of onset: Typically childhood to adolescence (3-15 years), though can present in adulthood (PMID: 29115605)
• Severity: Variable, from asymptomatic carriers with only abnormal EOG to severe central vision loss
• Progression: Slowly progressive over decades; mean annual BCVA loss 0.013 logMAR/year
• Frequency: Characteristic bilateral "egg-yolk" lesion in most symptomatic individuals; rare unilateral presentation documented (PMID: 40556259, PMID: 39992563)

The largest natural history study (222 patients, 141 families, mean follow-up 9.7 years) reported: "Mean BCVA was 0.37 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, 20/47) for the right eye and 0.33 logMAR (Snellen equivalent, 20/43) for the left eye at presentation, with a mean annual loss rate of 0.013 logMAR and 0.009 logMAR, respectively" (PMID: 38278445).

Structural progression: "Mean central retinal thickness on OCT at baseline was 337.2 um for the right eye and 341.1 um for the left eye, with a mean annual thickness loss of 5.7 and 5.2 um, respectively" (PMID: 40086732).

Key Symptoms and Signs

1. Central visual loss (HP:0007663) - Progressive, typically presenting in first or second decade
2. Vitelliform macular lesion (HP:0007677) - Bilateral yellow subretinal deposits
3. Reduced EOG light rise (HP:0030453) - Arden ratio <1.5; hallmark finding
4. Metamorphopsia (HP:0012508) - Distortion of central vision
5. Reduced color vision - Tritan-axis deficit in ~50% of ARB patients (PMID: 34015078)
6. Subretinal fluid accumulation (HP:0031526) - Common in BVMD and ARB
7. Choroidal neovascularization (HP:0011506) - Complication in advanced stages

Autosomal Recessive Bestrophinopathy (ARB)

ARB presents with distinct additional features:

"Anterior features included shallow anterior chambers (16/17), ciliary pronation (16/17), iris bombe (13/17), iridoschisis (2/17), iris plateau (1/17), narrow angles (16/17) and reduced axial lengths (16/17)." (PMID: 39048936)

ARB visual decline: "Mean presenting VA was 0.52 +/- 0.36 logarithm of the minimum angle of resolution (logMAR), and final VA was 0.81 +/- 0.75 logMAR. The mean rate of change in VA was 0.05 +/- 0.13 logMAR/year." (PMID: 33039401)

Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC)

ADVIRC is an extremely rare bestrophinopathy with distinctive developmental and degenerative features:

"Clinical features observed included angle closure glaucoma (n = 2), microcornea with shallow anterior chamber (n = 1), iris dysgenesis (n = 2), cataracts (n = 4), classical peripheral concentric band of retinal hyperpigmentation (n = 5), and optic nerve dysplasia (n = 1)." (PMID: 21072067)

"This report highlights the high phenotypic variability of autosomal dominant vitreoretinochoroidopathy, which may be misdiagnosed, especially in advanced forms with severe generalized photoreceptor dysfunction mimicking retinitis pigmentosa." (PMID: 29370033)

Retinitis Pigmentosa 50 (RP50)

RP50 presents with classic RP features including bone spicule pigmentation (HP:0000510), progressive visual field constriction (HP:0001133), night blindness (HP:0000662), reduced ERG amplitudes, and cystoid macular edema (HP:0040049) responding to oral acetazolamide (PMID: 29503890).

Quality of Life Impact

• Psychosocial burden scores in inherited retinal diseases exceed a mean of 6/10 across all domains (PMID: 40993143)
• Central vision loss significantly impacts reading, driving, and face recognition
• Most BVMD patients retain peripheral vision, maintaining independence for decades
• ARB patients face additional risk of acute vision loss from angle-closure glaucoma

4. Genetic/Molecular Information

Causal Gene

"Human bestrophin-1 (hBest1) is a calcium-activated chloride channel from the retinal pigment epithelium... KpBest is a pentamer that forms a five-helix transmembrane pore, closed by three rings of conserved hydrophobic residues, and has a cytoplasmic cavern with a restricted exit." (PMID: 25324390)

Pathogenic Variants

Variant Types and Classification

• Missense variants: Most common (~85-90%); predominantly in exons 2-8
• Nonsense variants: Less common, typically in ARB
• Frameshift variants: Associated with ARB when biallelic
• Splice-site variants: Including deep intronic variants (DIVs)

ClinVar statistics (May 2026): 1,047 total BEST1 variant entries: 455 pathogenic, 238 likely pathogenic (693 combined P/LP). This represents one of the largest variant databases for any inherited macular dystrophy gene.

Notable Variants

Deep Intronic Variants (Missing Heritability)

"Subsequent WGS, combined with supplementary Sanger sequencing, revealed three missing DIVs (c.1101-491A>G, c.867+97G>A, and c.867+97G>T) in 20 families. The novel DIV c.1101-491A>G caused an abnormal splicing resulting in a 204-nt pseudoexon (PE) insertion, whereas c.867+97G>A/T relatively strengthened an alternative donor site, resulting in a 203-nt intron retention (IR)." (PMID: 37747403)

Functional Consequences

• Dominant mutations (BVMD, ADVIRC): Primarily dominant-negative — mutant subunits incorporate into pentameric channel, disrupting function. Some mutations (p.P233L, p.P346H) undergo Hsp70/CHIP ubiquitination at Lys149: "Mutant bestrophin-1 proteins p.P346H and p.P233L undergo ubiquitination and degradation, preventing their localization to the cell membrane of MDCK II cells and the RPE of zebrafish, thereby reducing chloride channel activity." (PMID: 41456629)
• Recessive mutations (ARB, RP50): Loss-of-function — biallelic null or hypomorphic alleles that eliminate or severely reduce channel activity.

Modifier Genes

No modifier genes conclusively identified. Intrafamilial phenotypic variability strongly suggests genetic modifiers. "The features and combinations of different BEST1 mutations as well as epistatic effects may influence phenotype expression." (PMID: 25489231)

Protein Interaction Network (STRING-DB)

BEST1 also interacts directly with CaV1.3 (CACNA1D) L-type calcium channel (PMID: 26427483).

Epigenetic and Chromosomal Information

No specific epigenetic alterations or chromosomal abnormalities reported. All pathogenic events occur at the nucleotide level.

5. Environmental Information

Environmental Factors

No environmental toxins, radiation, or occupational exposures are causative or modifying. The disease is entirely genetic.

Lifestyle Factors

No specific lifestyle factors established. General retinal-protective measures (UV protection, antioxidant supplementation) may be theoretically beneficial but lack specific evidence.

Infectious Agents

Not applicable.

6. Mechanism / Pathophysiology

Molecular Pathways

Primary: Calcium-Activated Chloride Channel Dysfunction

Bestrophin-1 forms a pentameric CaCC on the basolateral membrane of RPE cells, activated by intracellular Ca2+ at ~150-200 nM. The channel conducts Cl- and HCO3- ions, regulating transepithelial potential and fluid transport.

"Human bestrophin-1 (hBest1) is a calcium-activated chloride channel from the retinal pigment epithelium... KpBest is a pentamer that forms a five-helix transmembrane pore" (PMID: 25324390)

"Mutations in BEST1, encoding Bestrophin-1 (Best1), cause Best vitelliform macular dystrophy (BVMD) and other inherited retinal degenerative diseases. Best1 is an integral membrane protein localized to the basolateral plasma membrane of the retinal pigment epithelium (RPE). Data from numerous in vitro and in vivo models have demonstrated that Best1 regulates intracellular Ca2+ levels." (PMID: 25878489)

Secondary: BEST1-CaV1.3 Calcium Channel Axis

"Previously we showed that bestrophin-1 interacts with L-type Ca2+ channels of the CaV1.3 subtype and that the endogenously expressed bestrophin-1 is required for intracellular Ca2+ regulation. A hallmark of Best's disease is the fast lipofuscin accumulation occurring already at young ages." (PMID: 26427483)

This interaction modulates phagocytosis of photoreceptor outer segments (POS). CaV1.3 expression is diurnally regulated (higher in afternoon), and CaV1.3-/- mice show shifted circadian POS phagocytosis, linking BEST1 to circadian RPE function.

Cellular Processes

1. Impaired Fluid Transport (GO:0042044)

"Fluid transport from apical to basal was significantly decreased in ARB iPSC-RPE compared with BD iPSC-RPE or control iPSC-RPE." (PMID: 32882766)

2. Impaired Phagocytosis (GO:0006909)

"When tested for the ability to phagocytose photoreceptor outer segments, ARB iPSC-RPE exhibited impaired internalization. These data suggest that impaired phagocytosis is a trait common to the bestrophinopathies." (PMID: 29540715)

3. Epithelial-Mesenchymal Transition (GO:0001837) and Inflammation

"Gene Set Enrichment Analysis confirmed that ARB iPSC-RPE exhibited significant enrichments of epithelial-mesenchymal transition gene set and TNF-alpha signaling via NF-kappaB gene set compared to control iPSC-RPE or BD iPSC-RPE." (PMID: 32882766)

Protein Quality Control: Hsp70/CHIP Ubiquitination Pathway

"Lys149 was identified as the site responsible for ubiquitination of p.P346H- and p.P233L-bestrophin-1, mediated by Hsp70 and the C-terminal Hsp70-interacting protein (CHIP). Mutant bestrophin-1 proteins p.P346H and p.P233L undergo ubiquitination and degradation, preventing their localization to the cell membrane of MDCK II cells and the RPE of zebrafish, thereby reducing chloride channel activity." (PMID: 41456629)

Causal Chain: Mutation to Clinical Disease

BEST1 mutation
    |
    v
Dysfunctional Bestrophin-1 channel
(reduced Cl- conductance + altered Ca2+ signaling via BEST1-CaV1.3 axis)
    |
    +---> Impaired transepithelial fluid transport --> Subretinal fluid accumulation
    |
    +---> Defective POS phagocytosis --> Lipofuscin/vitelliform material accumulation
    |
    +---> EMT activation + NF-kB/TNF-alpha signaling --> RPE dysfunction
    |
    v
Progressive RPE atrophy --> Secondary photoreceptor degeneration --> Vision loss

Lipid Membrane Interactions

"Interactions between hBest1, sphingomyelins, phosphatidylcholines and cholesterol are crucial for hBest1 association with cell membrane domains and its biological functions." (PMID: 33451008)

Purinergic Signaling

"hBest1 mutants that are known to cause autosomal dominant macular dystrophy (Best disease) did not produce a Cl- current. Bestrophins were colocalized and showed molecular and functional interaction in HEK293 cells." (PMID: 19130075)

GO Terms

Molecular Function: - GO:0005229 - intracellularly calcium-gated chloride channel activity - GO:0005254 - chloride channel activity - GO:0160133 - bicarbonate channel activity - GO:0042802 - identical protein binding (homo-pentamer formation)

Biological Process: - GO:1902476 - chloride transmembrane transport - GO:0006821 - chloride transport - GO:0050908 - detection of light stimulus involved in visual perception - GO:0006909 - phagocytosis - GO:0042044 - fluid transport - GO:0001837 - epithelial to mesenchymal transition (disease mechanism) - GO:0006954 - inflammatory response (TNF-alpha/NF-kappaB in ARB)

Cellular Component: - GO:0016323 - basolateral plasma membrane (primary localization) - GO:0034707 - chloride channel complex - GO:0098857 - membrane microdomain (lipid rafts) - GO:0005783 - endoplasmic reticulum

Cell Types (CL Terms)

• CL:0002586 - retinal pigment epithelial cell (primary)
• CL:0000604 - retinal rod cell (secondary degeneration)
• CL:0000573 - retinal cone cell (secondary degeneration)

Chemical Entities (CHEBI Terms)

7. Anatomical Structures Affected

Organ Level

• Primary organ: Eye (UBERON:0000970)
• Primary structure: Retina (UBERON:0000966), specifically the macula (UBERON:0000053)
• Secondary involvement: Anterior segment (in ARB and ADVIRC)
• Body system: Visual system (UBERON:0002104)

Tissue and Cell Level

Subcellular Level

• Basolateral plasma membrane (GO:0016323) - BEST1 primary localization
• Endoplasmic reticulum (GO:0005783) - BEST1 also localizes here; misfolded mutants accumulate
• Phagolysosomes (GO:0001891) - Impaired in bestrophinopathies

Localization

• Bilateral involvement is the rule; rare unilateral presentations documented (PMID: 39992563; PMID: 40556259)
• BVMD primarily affects fovea/macula; ARB shows diffuse posterior pole to panretinal involvement; ADVIRC characteristically affects the peripheral retina

8. Temporal Development

Onset

Progression

BVMD: Slow progression through well-defined stages over decades. Mean annual BCVA loss: 0.013 logMAR/year (right eye), 0.009 logMAR/year (left eye) over 9.7-year mean follow-up. Mean central retinal thickness loss: 5.7 um/year (PMID: 38278445; PMID: 40086732).

ARB: More rapid progression. Rate of VA change: 0.05 logMAR/year. SW-AF severity grading: 21% grade 1 (isolated macular), 44% grade 2 (multifocal/diffuse posterior pole), 35% grade 3 (panretinal) (PMID: 41421761).

Disease duration: Chronic lifelong. No spontaneous remission.

Critical Periods

• Childhood/adolescence: Period of vitelliform lesion appearance in BVMD
• CNV development: Can occur at any stage; treatable if detected early; reported in children as young as 8 years (PMID: 26225154)

9. Inheritance and Population

Epidemiology

• BVMD prevalence: Estimated 1:10,000 to 1:67,000 (varies by population)
• ARB prevalence: Much rarer; estimated <1:100,000
• Overall: Among the most common inherited macular dystrophies

Inheritance Patterns

"Recessively inherited VMD (arVMD) has been reported, suggesting that dominant and recessive BEST1-related retinopathies represent a single disease spectrum." (PMID: 34015078)

Penetrance and Expressivity

• Penetrance: Incomplete in many families. Some heterozygous carriers have only abnormal EOG without fundus lesions. "Family study confirmed the variable penetrance and expressivity of the disease." (PMID: 31570112)
• Expressivity: Highly variable. Within a single family, different stages and severity observed with the same mutation.

Founder Effects

• c.867+97G>A: Chinese ARB founder variant (PMID: 37747403)
• c.365G>C (p.Arg122Pro): Egyptian ARB founder variant (PMID: 40414863)

Population Demographics

• Worldwide distribution; no specific ethnic predilection for BVMD
• Sex ratio: Approximately 1:1 (slight male predominance in largest cohort, 57.2%, likely ascertainment bias)
• Consanguinity: Significantly increases ARB risk (PMID: 21738390; PMID: 40414863)

10. Diagnostics

Clinical Tests

Electro-oculogram (EOG)

Gold standard functional test. Measures the Arden ratio (light peak / dark trough). Normal >1.65-1.80; BVMD <1.5; ARB often <1.1. Reduced bilaterally even with unilateral fundus lesions. "The Arden ratio was significantly lower in ARB patients and in eyes with stage 5 of BVMD." (PMID: 34327816)

Optical Coherence Tomography (OCT)

Demonstrates subretinal hyperreflective material, subretinal fluid, RPE detachment/irregularity, and progressive outer retinal thinning.

Fundus Autofluorescence (FAF)

Hyperautofluorescent vitelliform deposits; hypoautofluorescent atrophic areas. Useful for distinguishing ARB from BVMD and for staging.

Electroretinography (ERG)

Full-field ERG typically normal in BVMD; reduced in ARB. Helps distinguish from generalized retinal dystrophies.

Deep Learning/AI Diagnosis

~90% accuracy in differentiating BVMD from AVMD on OCT and BAF imaging (PMID: 35882966).

Genetic Testing

Recommended approach: 1. First-line: Targeted BEST1 sequencing (all 11 exons + flanking intronic regions) 2. If negative: Gene panel for inherited macular dystrophies 3. Complex cases: WES or WGS (critical for deep intronic variants)

"Subsequent WGS, combined with supplementary Sanger sequencing, revealed three missing DIVs in 20 families." (PMID: 37747403)

Third-generation sequencing (PacBio SMRT) has also been successfully used (PMID: 38619684).

Differential Diagnosis

Screening

• Cascade screening of family members via EOG and genetic testing
• No population-level screening currently recommended

MAXO Terms

• MAXO:0010034 (electro-oculography)
• MAXO:0010033 (electroretinography)
• MAXO:0010032 (optical coherence tomography)
• MAXO:0000079 (genetic testing)

11. Outcome / Prognosis

Survival and Mortality

Life expectancy is normal. Bestrophinopathies are purely ocular with no systemic manifestations and no disease-specific mortality.

Morbidity and Function

• BVMD: Many maintain functional vision (>20/40) for decades. Mean annual BCVA loss only 0.013 logMAR/year.
• ARB: More rapid decline. Mean presenting VA: 0.52 logMAR (~20/66); final VA: 0.81 logMAR (~20/130); rate: 0.05 logMAR/year (PMID: 33039401).
• Complications: CNV (any stage, treatable with anti-VEGF); angle-closure glaucoma (29% in ARB; PMID: 41421761); macular hole (rare).

Prognostic Factors

• Zygosity: Biallelic (ARB) worse than heterozygous (BVMD)
• Disease stage: Advanced stages (4-5) have poorer outcomes
• SW-AF grade: Higher grades in ARB correlate with more extensive dysfunction
• CNV development: If treated promptly, outcomes can be reasonable

12. Treatment

Current Standard of Care

No approved disease-modifying treatment. Management is supportive and complication-directed.

Pharmacotherapy

Anti-VEGF Therapy (for CNV)

• Bevacizumab (off-label intravitreal): Effective for CNV regression in BVMD and ARB (PMID: 20195045; PMID: 26225154; PMID: 36729806)
• Ranibizumab, Aflibercept: Also used

Photodynamic Therapy (PDT)

Long-term safety demonstrated in pediatric BVMD with CNV (PMID: 25675349).

Carbonic Anhydrase Inhibitors

Oral acetazolamide for cystoid macular edema in RP50 (PMID: 29503890).

Advanced Therapeutics: Gene Therapy

Preclinical evidence: "Gene augmentation in iPSC-RPE fully restored BEST1 calcium-activated chloride channel activity and improved rhodopsin degradation in an iPSC-RPE model of recessive bestrophinopathy as well as in two models of dominant Best disease caused by different mutations in regions encoding ion-binding domains. A third dominant Best disease iPSC-RPE model did not respond to gene augmentation, but showed normalization of BEST1 channel activity following CRISPR-Cas9 editing of the mutant allele." (PMID: 32707085)

Canine studies: "the rAAV2/2 vector serotype carrying either GFP reporter or BEST1 transgene under control of human VMD2 promoter was safe, and enabled specific transduction of the RPE cell monolayer that was stable for up to 6 months post injection" (PMID: 24143172)

Advanced Therapeutics: Gene Editing

CRISPR/Cas9 and Cas12 correction using lipoplexes achieved HDR in iPSC-RPE from Best disease patients (PMID: 41827889). Particularly relevant for dominant-negative mutations non-responsive to gene augmentation.

Active Clinical Trials

Supportive Care

• Low vision aids and rehabilitation (MAXO:0000127)
• Regular monitoring for CNV and glaucoma
• Glaucoma management for angle-closure complications
• Genetic counseling (MAXO:0000950)

MAXO Terms

• MAXO:0001001 (gene therapy)
• MAXO:0001085 (genome editing therapy)
• MAXO:0001298 (intravitreal injection)
• MAXO:0000015 (photodynamic therapy)
• MAXO:0000127 (low vision rehabilitation)
• MAXO:0000950 (genetic counseling)

13. Prevention

Primary Prevention

As a genetic disorder, primary prevention is limited to reproductive counseling: - Genetic counseling for at-risk families - Preimplantation genetic testing (PGT) for families with known pathogenic variants - Prenatal diagnosis technically possible but not routinely performed

Secondary Prevention (Early Detection)

• Cascade genetic testing of at-risk family members
• EOG screening in family members of affected individuals
• Regular ophthalmologic monitoring for early CNV and glaucoma detection

Tertiary Prevention (Complication Prevention)

• Regular IOP monitoring in ARB for angle-closure glaucoma
• Prophylactic laser peripheral iridotomy in ARB patients with narrow angles
• Amsler grid self-monitoring for early CNV detection
• Patient education on symptoms requiring urgent evaluation

Genetic Counseling

• BVMD/ADVIRC (AD): 50% recurrence risk to offspring
• ARB/RP50 (AR): 25% recurrence risk to siblings of affected individual
• Variable penetrance and expressivity must be discussed
• Carrier testing available for recessive forms

14. Other Species / Natural Disease

Canine Bestrophinopathies

Canine multifocal retinopathy (cmr) is the best-characterized veterinary counterpart:

Canine cmr recapitulates human bestrophinopathy features and has been instrumental for gene therapy development (PMID: 24143172; PMID: 33606121).

BEST1 Orthologs

Comparative Biology

BEST1 is highly conserved across vertebrates and invertebrates. The calcium-activated chloride channel function is conserved from bacteria to humans (PMID: 25324390). Not zoonotic; not transmissible between species.

15. Model Organisms

Mouse Models

• Best1-Cre transgenic mice: Standard tool for RPE-specific conditional gene targeting (used for autophagy, potassium channel, Yap1, glucose transport studies: PMID: 26075877; PMID: 30009826; PMID: 32223016; PMID: 30462537)
• Limitation: Mice lack a true macula, limiting translational relevance for macular-predominant disease

Canine Models

Naturally occurring cmr1/cmr2/cmr3 — most clinically relevant large-animal model for therapeutic development. AAV gene therapy safety and efficacy demonstrated (PMID: 24143172).

Zebrafish Models

Used for in vivo validation of mutant pathogenicity. Overexpression of human BEST1 mutants (p.P233L, p.P346H) demonstrated mislocalization and retinal structural disruption (PMID: 41456629).

Drosophila Models

dBest1 identified as the Drosophila Cl_swell channel in genome-wide RNAi screen (PMID: 23056495). Currents regulated by CaMKII-dependent phosphorylation (PMID: 23554946). Human disease mutation W94C reduced endogenous Cl_swell current.

iPSC-RPE Models (In Vitro)

Most physiologically relevant disease model:

"This protocol describes how to generate human RPEs bearing BEST1 disease-causing mutations by induced differentiation from human pluripotent stem cells... provides a very powerful disease-in-a-dish model for BEST1-associated retinal conditions." (PMID: 30199040)

Model Limitations

• Mouse: Lacks macula; mild phenotype
• Canine: Expensive; limited genetic manipulation tools
• Zebrafish: No fovea; overexpression may not fully recapitulate endogenous disease
• Drosophila: dBest1 has distinct swell-activation; limited disease relevance
• iPSC-RPE: Lacks complex retinal architecture and photoreceptor interactions

Key Findings Summary

F001: BEST1 Pentameric CaCC Structure

Crystal structure of bacterial homolog KpBest1 revealed pentameric architecture. BEST1 is a Ca2+-activated Cl- channel expressed on basolateral membrane of RPE (PMID: 25324390; PMID: 25878489).

F002: Five Distinct Bestrophinopathy Phenotypes

Over 200 pathogenic mutations cause BVMD, ARB, ADVIRC, RP50, and AVMD. Biallelic variants cause more severe phenotypes, supporting a disease spectrum concept (PMID: 31884648; PMID: 34015078).

F003: ARB Natural History Quantified

34 ARB patients: median baseline age 32 years, 29% with PAC, mean VA decline 0.05 logMAR/year. Anterior segment features in >90% of Chinese patients (PMID: 41421761; PMID: 33039401; PMID: 39048936).

F004: Gene Therapy Preclinical Promise

AAV augmentation restored CaCC activity in 3/4 iPSC-RPE models; CRISPR rescued the fourth dominant-negative model. Canine rAAV2/2-BEST1 showed stable 6-month RPE transduction (PMID: 32707085; PMID: 24143172).

F005: iPSC-RPE Reveals Impaired Fluid Transport and Phagocytosis

ARB iPSC-RPE showed decreased fluid transport, EMT/NF-kB pathway enrichment, and impaired POS internalization (PMID: 32882766; PMID: 29540715).

F006: First Human Gene Therapy Trial

NCT07185256 (OPGx-BEST1, Phase 1b/2a) recruiting since September 2025. Subretinal AAV injection for BVMD/ARB.

F007: ADVIRC Clinical Characterization

Developmental anomalies (microcornea, iris dysgenesis, optic nerve dysplasia) plus peripheral retinal hyperpigmentation. High variability; may mimic RP (PMID: 21072067; PMID: 29370033).

F008: BEST1-CaV1.3 Phagocytosis Regulation

Bestrophin-1 interacts with CaV1.3 to regulate calcium and POS phagocytosis. CaV1.3 is diurnally regulated, linking to circadian RPE function (PMID: 26427483; PMID: 31930599).

F009: Deep Intronic Variants Resolve Missing Heritability

WGS identified three DIVs in Chinese ARB, resolving 20/63 pedigrees. c.867+97G>A is a Chinese founder allele (PMID: 37747403).

F010: ClinVar Variant Landscape

1,047 BEST1 variants; 693 P/LP. STRING-DB top partners: RPE65 (0.891), PRPH2 (0.868), ABCA4 (0.811).

F011: Ubiquitination Mechanism

Hsp70/CHIP E3 ligase ubiquitinates mutant BEST1 at Lys149 (p.P233L, p.P346H), causing degradation and membrane mislocalization. Validated in MDCK II cells and zebrafish (PMID: 41456629).

F012: BVMD Natural History (Largest Cohort)

222 patients, 141 families: mean presenting BCVA 0.37 logMAR, annual loss 0.013 logMAR/year, central retinal thickness 337 um declining 5.7 um/year (PMID: 38278445; PMID: 40086732).

Evidence Base

Key Literature

Limitations and Knowledge Gaps

1. Incomplete genotype-phenotype correlations: Despite 1,047 known variants, the relationship between specific mutations and clinical severity remains poorly understood.
2. Unknown modifier genes: Intrafamilial variability strongly suggests genetic modifiers, but none have been identified.
3. Limited natural history data for rare phenotypes: ADVIRC, RP50, and AVMD lack systematic longitudinal studies.
4. Absence of validated biomarkers: No blood-based or non-invasive biomarkers exist for disease monitoring.
5. Mouse model limitations: Mice lack a true macula, limiting translational relevance.
6. Gene therapy for dominant mutations: Optimal approach (augmentation vs. editing vs. knockdown-and-replace) undefined for each mutation class.
7. Long-term gene therapy safety: First human trial just begun; long-term outcomes and pediatric application remain unknown.
8. Environmental modifiers: Whether light exposure, nutrition, or other factors modify progression has not been studied.
9. Missing molecular diagnoses: Some ARB families remain genetically unresolved even with WGS.
10. Quality of life data: No disease-specific patient-reported outcome measures exist.

Proposed Follow-up Experiments / Actions

High Priority

1. Monitor NCT07185256 (OPGx-BEST1) trial outcomes: Phase 1b/2a results will define safety and preliminary efficacy of subretinal AAV-BEST1 gene therapy.
2. Expand WGS-based genetic testing: Implement WGS as standard for genetically unsolved ARB cases, particularly in populations with known deep intronic founder variants.
3. Develop mutation-specific therapeutic algorithms: Classify BEST1 mutations into gene augmentation-responsive vs. gene editing-requiring categories using iPSC-RPE modeling.
4. Investigate Hsp70/CHIP pathway as therapeutic target: Small-molecule chaperones or proteasome modulators that rescue mutant bestrophin-1 trafficking.

Medium Priority

1. Genome-wide modifier gene search: GWAS or WGS in large bestrophinopathy families with variable penetrance.
2. Develop bestrophinopathy-specific PROs: Create and validate disease-specific quality-of-life instruments for clinical trials.
3. Longitudinal ADVIRC and RP50 natural history registries.
4. Pharmacological chaperone screening for compounds promoting mutant bestrophin-1 folding.

Lower Priority

1. Single-cell transcriptomics of patient iPSC-RPE to characterize cellular heterogeneity.
2. CRISPR base editing approaches for common BEST1 missense mutations without requiring HDR.

Ontology Summary Table

Report generated: 2026-05-05. Based on systematic review of 108 PubMed-indexed publications and 12 confirmed findings across 5 research iterations. 47 primary literature citations with PMIDs. 86+ ontology term annotations across HPO, GO, CL, UBERON, CHEBI, MAXO, and MONDO.